- Home
- CWD vs MYNZ Comparison
CWD vs MYNZ Comparison
Compare CWD & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWD
- MYNZ
- Stock Information
- Founded
- CWD 2009
- MYNZ 2021
- Country
- CWD United States
- MYNZ Germany
- Employees
- CWD N/A
- MYNZ N/A
- Industry
- CWD Real Estate
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- CWD Finance
- MYNZ Health Care
- Exchange
- CWD Nasdaq
- MYNZ Nasdaq
- Market Cap
- CWD 12.1M
- MYNZ 10.5M
- IPO Year
- CWD 2023
- MYNZ 2021
- Fundamental
- Price
- CWD $0.50
- MYNZ $3.39
- Analyst Decision
- CWD
- MYNZ Buy
- Analyst Count
- CWD 0
- MYNZ 3
- Target Price
- CWD N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- CWD 244.5K
- MYNZ 177.3K
- Earning Date
- CWD 03-31-2025
- MYNZ 04-15-2025
- Dividend Yield
- CWD N/A
- MYNZ N/A
- EPS Growth
- CWD N/A
- MYNZ N/A
- EPS
- CWD N/A
- MYNZ N/A
- Revenue
- CWD $51,119,000.00
- MYNZ $893,991.00
- Revenue This Year
- CWD N/A
- MYNZ $20.94
- Revenue Next Year
- CWD $33.62
- MYNZ $18.01
- P/E Ratio
- CWD N/A
- MYNZ N/A
- Revenue Growth
- CWD N/A
- MYNZ N/A
- 52 Week Low
- CWD $0.37
- MYNZ $0.18
- 52 Week High
- CWD $1.05
- MYNZ $8.20
- Technical
- Relative Strength Index (RSI)
- CWD 38.38
- MYNZ 37.25
- Support Level
- CWD $0.48
- MYNZ $2.72
- Resistance Level
- CWD $0.68
- MYNZ $3.64
- Average True Range (ATR)
- CWD 0.09
- MYNZ 0.52
- MACD
- CWD -0.01
- MYNZ -0.09
- Stochastic Oscillator
- CWD 8.46
- MYNZ 25.57
About CWD CaliberCos Inc.
CaliberCos Inc is an asset management firm, whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. Majority of revenue is derived from Asset management fees segment.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.